Fact CheckerSign in

NCT06339034Active, not recruitingPhase 1/2

Repurposing Lithium for Parkinson's Disease: a RCT

Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 26 Oct 2026

Brief summary (registry, in English)

This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
20 (estimated)
First submitted
24 Mar 2024
Start date
3 Jul 2024
Primary completion date
Aug 2027
Lead sponsor
State University of New York at Buffalo
NCT number
NCT06339034

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 20
  • From 3 Jul 2024 to the primary completion date, Aug 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Have PD for \>4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD.
    • Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion.
    • Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks.
    • Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.

Who the study is looking for

  • Have PD for \<4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD.
    • Have no use of tobacco or THC products for \>1 year. Have stable PD medications for \>30 days without current need for adjustments in the investigator's opinion.
    • Have stable psychiatric and diuretic medications for \>60 days with no anticipated need for changes for at least 24 weeks.
    • Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.

Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
UBMD Neurology
Coordinator of this site? Confirm its status
WilliamsvilleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.